CA
NZ
UK
AU
IND
US
No release, filing or analyst action dated November 9 or November 10, 2026 was identified in published coverage, so the cause of the fall is not established. The relevant context is the 1-for-40 reverse split announced on July 17, 2026 and effective on July …
Key HighlightsTriSalus Life Sciences (NASDAQ:TLSI) closed at USD 2.46 on Tuesday, November 10, 2026, down 23.76% from a calculated prior close of USD 3.23, among the biggest decliners in a published screener snapshot of 4,625 names.The third quarter 2026 release dated November 10, 2026 …
The identified catalyst is the reverse split. The 8-K signed November 4, 2026 said a certificate of amendment was filed in Delaware on November 2, 2026, the split took effect at 5:00 p.m. ET on November 5, 2026, and split-adjusted shares began trading at …
No company release, filing or analyst action dated November 9 or November 10, 2026 was identified in published coverage after two searches, so no catalyst identified is the accurate statement. The latest dated results found are the third quarter 2025 figures in an 8-K …
No company release, filing or analyst action dated November 9 or November 10, 2026 was identified in published coverage after repeated searches, so no catalyst identified is the accurate statement. Recent dated items include the October 23, 2026 notice that the company regained compliance …
Key HighlightsEquipmentShare (NASDAQ:EQPT) traded at USD 12.83 in the November 10, 2026 session, down 20.85% from a calculated prior close of USD 16.21, onVolumeof 1.91 million shares and relative volume of 0.62.Market value was USD 3.26 billion, trailing diluted EPS was USD 0.13 and …
Key HighlightsVivakor (NASDAQ:VIVK) traded at USD 0.3003 on November 10, 2026, down 20.83% from a calculated prior close of USD 0.3793, onVolumeof 26.74 million shares and relative volume of 0.95.The company release dated November 9, 2026 said the last of four convertible notes, with …
The most likely driver is the combination of slowing growth, lower adjusted EBITDA and soft guidance, although no published coverage confirmed a single cause. Fourth quarter revenue is guided to USD 133 million to USD 136 million, flat to up 2%, with billings growth …
No published coverage confirmed the cause, but the results offer candidates. Fourth quarter adjusted EBITDA guidance of USD 31.0 million to USD 32.0 million sits on revenue of USD 130.5 million to USD 133.5 million and contribution ex-TAC of USD 80.5 million to USD …
Key HighlightsJIADE Limited (NASDAQ:JDZG) closed at USD 0.2010 on Tuesday, November 10, 2026, down 19.50% from a calculated prior close of USD 0.2497, among the largest decliners in a published screener snapshot of 4,625 names.Volume was 3.42 million shares at a relativeVolumeof 0.10, so …
Please wait processing your request...